Pfizer $14 billion acquisition of Medivation

Overview:

• Pfizer has acquired cancer drug pharmaceutical company Medivation in a $14 billion deal.
• Medivation is known especially for its new prostate cancer drug Xtandi.
• The deal comes shortly after Medivation rejected a smaller offer by Sanofi, and only a few months after Pfizer's $5.2 billion purchase of Anacor.
• Ropes & Gray (Christopher Comeau, Paul Kinsella) advised Pfizer.
• Wachtell Lipton Rosen & Katz (Daniel Neff, Trevor Norwitz, Mark Gordon, Gregory Ostling, Ronald Chen) and Cooley (Jamie Leigh, Kenn Guernsey) advised Medivation.
• Davis Polk & Wardwell (Alan Denenberg) represented Medivation financial adviser JPMorgan Securities.

Kurt Stumpo - Journalist - North America and the Carribean